Dynavax Technologies (DVAX) Q3 2024 earnings summary

Executive summary

• HEPLISAV-B net product revenue reached $79.3M in Q3 2024, up 27% year-over-year, driving record profitability and increased U.S. market share to ~44%.

• Net income for Q3 2024 was $17.6M ($0.13 per share basic), with cash and marketable securities at $764M as of September 30, 2024.

• Discontinued Tdap-1018 program after Phase 1 results did not show a differentiated profile; focus remains on pipeline investments.

• Board authorized a $200M share repurchase program in November 2024, reflecting strong financial position and capital return strategy.

• Actively enrolling in Phase 1/2 trial for shingles vaccine Z1018, with top-line data expected in H2 2025.

Financial highlights

• Q3 2024 total revenues were $80.6M, with HEPLISAV-B product revenue at $79.3M and other revenue at $1.3M.

• Gross margin for HEPLISAV-B improved to 84% in Q3 and 82% for the first nine months, exceeding full-year guidance of ~80%.

• R&D expenses were $14.4M; SG&A expenses rose to $43.1M, both increasing year-over-year due to pipeline and commercial investments.

• Quarterly net income was $17.6M, up 23% year-over-year; cash and marketable securities totaled $764M, up $28M in Q3.

• Cost of sales for HEPLISAV-B decreased 1% in Q3 due to lower per-unit manufacturing costs.

Outlook and guidance

• Full-year 2024 HEPLISAV-B net product revenue guidance narrowed to $265–$270M, with gross margin expected at ~80%.

• R&D expenses forecasted at $55–$65M; SG&A at $170–$180M for 2024.

• Anticipates full-year profitability and positive net income for 2024.

• Cash and securities of $764M expected to fund operations for at least 12 months.

• U.S. HEPLISAV-B market projected to exceed $900M by 2030, targeting at least 60% market share and double-digit annual sales growth.